AbbVie’s former blockbuster testosterone-replacement treatment AndroGel will be at the center of a class action lawsuit set to go to trial this year, alleging, in short, that previously healthy men ...

Testosterone therapy, in which testosterone is administered to men with low levels of the hormone, has been a controversial topic, with some advocating for the therapy as a way to restore vitality in ...

(AP) — The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective ...

Jeffrey Konrad, a traffic consultant in Tennessee, started taking AbbVie’s heavily advertised testosterone drug AndroGel in 2010 and suffered a heart attack shortly thereafter. Now he’s one of 4,100 ...

AbbVie announced that the FDA has approved a new packaging option for AndroGel (testosterone gel) 1.62%. Besides the previously approved metered-dose pump packaging, Androgel 1.62% will also be ...

AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, ...

Thousands of federal lawsuits alleging harm from AbbVie’s AndroGel are on the cusp of being settled, marking the end of a long legal saga about the safety of testosterone therapy and the marketing ...

AndroGel (testosterone gel) is prescribed to treat low testosterone levels. AndroGel’s cost may depend on your dosage and whether you have health insurance. It also may depend on the pharmacy you use ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...

Please provide your email address to receive an email when new articles are posted on . Abbott received FDA approval for a new, low-volume testosterone formulation to treat low testosterone in men.

San Francisco, Calif. and Torrance, Calif. (June 20, 2002) – A Phase 3 study conducted at multiple research centers in the U.S. under the direction of Ronald Swerdloff, MD, Principal Investigator at ...